#daraxonrasib
Latest news and interesting information about daraxonrasib.
Revolution Medicines Phase 3 Trial Results
Revolution Medicines announces positive Phase 3 trial results for daraxonrasib in pancreatic cancer, showing significant survival benefit.
Bernstein Starts Revolution Med at Market Perform
Bernstein initiates Revolution Medicines coverage with Market Perform rating and $151 target. Stock trades at $153.73.
Revolution Medicines Phase 3 Results Webcast
Revolution Medicines webcast on Phase 3 RASolute 302 results for daraxonrasib in pancreatic cancer. Learn more.
US cancer centers rush for Revolution drug
U.S. cancer centers are rushing to enroll patients in an early access program for Revolution Medicines' promising pancreatic cancer drug.
...